Guidelines for the Treatment of Benign Prostatic Hyperplasia

Yunuo Wu, PharmD; Michael H. Davidian, MD, MS; Edward M. DeSimone II, RPh, PhD, FAPhA


US Pharmacist. 2016;41(8):36-41. 

In This Article

Abstract and Introduction


Benign prostatic hyperplasia (BPH) is a common disorder in men with an incidence that increases with age. BPH often requires therapy when patients begin to experience lower urinary tract symptoms that affect quality of life. Current management strategies involve lifestyle modifications, pharmacotherapy, phytotherapy, and surgical interventions as indicated. Pharmacists are in the unique position of being accessible sources of healthcare information for the BPH patient population. Understanding the symptoms of this disorder and therapy options will be beneficial for pharmacists who have increased chances to answer BPH-related questions from their patients.


Benign prostatic hyperplasia (BPH) is a common disorder that presents in men and increases in incidence with age. It is characterized by the nonmalignant growth of the prostate gland that occurs in most men >40 years of age. The prevalence of BPH, as seen in several autopsy studies around the world, is estimated to be approximately 20% for men in their 40s, up to 60% for men in their 60s, and up to 90% for men in their 70s and 80s.[1] Although almost all men will develop histologic or microscopic evidence of BPH by their eighth decade of life, the condition does not require treatment until it becomes symptomatic.